Program
tafolecimab
Also written as “IBI306”, “tafolecimab (a modified manufacturing process)” and “IBI306 450mg SC Q4W”.
Its studies are mostly in Hypercholesterolemia · Hyperlipoproteinemia Type II · Homozygous Familial Hypercholesterolemia, led by Innovent Biologics.
Furthest: phase 3, since Jul 22, 20198 company-led studies, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Innovent Biologics | 81 open or running | phase 3since Jul 22, 2019 | Nov 27, 2017 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 27, 2017First study: phase 1 study in HypercholesterolemiaFirst studyNCT03366688 · 58 enrolled · China
- Jan 22, 2019Phase 2 study in HypercholesterolemiaNCT03815812 · 60 enrolled · China
- Jul 22, 2019Phase 3 study in Homozygous Familial HypercholesterolemiaNCT04031742 · 18 enrolled · China
- Nov 25, 2019Phase 3 study in Heterozygous Familial HypercholesterolemiaNCT04179669 · 149 enrolled · China
- Feb 26, 2020Phase 3 study in HypercholesterolemiaNCT04289285 · 804 enrolled · China
- Jan 12, 2021Phase 3 study in HypercholesterolemiaNCT04709536 · 306 enrolled · China
- Mar 6, 2023Phase 1 study in Healthy Male SubjectsNCT05792917 · 166 enrolled · China
- Mar 11, 2026Phase 3 study in Hyperlipoproteinemia Type IINCT07473960 · 198 enrolled · China
TargetBeta
PCSK9 →read by rule
“A human immunoglobulin G2 (IgG2) monoclonal antibody directed against human proprotein convertase subtilisin/kexin type 9 (PCSK9), ”NCIt, by rule
“Subtilisin/kexin type 9 inhibitor”ChEMBL 37, by rule
Other programs on PCSK9
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| alirocumabrule | Sanofi | phase 4 | 48 |
| evolocumabrule | Amgen | phase 4 | 45 |
| inclisiranrule | Novartis | phase 4 | 37 |
| lerodalcibeprule | lib-therapeutics-llc | phase 3 | 14 |
| recaticimabrule | Jiangsu HengRui Medicine | phase 3 | 7 |
| QLC7401rule | Qilu Pharmaceutical | phase 3 | 5 |
| SAL003rule | Shenzhen Salubris Pharmaceuticals | phase 3 | 3 |
| VERVE-102 | Eli Lilly | phase 2 | 2 |
| DNV001rule | hangzhou-dinovate-biotech-co-ltd | phase 2 | 1 |
| RBD7022rule | Qilu Pharmaceutical | phase 1 | 2 |
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07473960Hyperlipoproteinemia Type II · China | 3 | Active, not recruiting | Sep 6, 2026 | 198 |
| NCT05792917Healthy Male Subjects · China | 1 | Completed | Mar 26, 2023 | 166 |
| NCT04709536Hypercholesterolemia · China | 3 | Completed | Nov 9, 2021 | 306 |
| NCT04289285Hypercholesterolemia · China | 3 | Completed | Feb 9, 2022 | 804 |
| NCT04179669Heterozygous Familial Hypercholesterolemia · China | 3 | Completed | Jun 30, 2021 | 149 |
| NCT04031742Homozygous Familial Hypercholesterolemia · China | 3 | Completed | Dec 30, 2021 | 18 |
| NCT03815812Hypercholesterolemia · China | 2 | Completed | Dec 25, 2019 | 60 |
| NCT03366688Hypercholesterolemia · China | 1 | Completed | Nov 5, 2018 | 58 |
How it is read
Names in the registry
- “IBI306”, 8 entries
- “tafolecimab (a modified manufacturing process)”, 1 entry
- “IBI306 450mg SC Q4W”, 1 entry
- “IBI306 600mg SC Q6W”, 1 entry
Conditions, from the studies’ own filings
- Hypercholesterolemia, 4 studies
- Hyperlipoproteinemia Type II, 2 studies
- Homozygous Familial Hypercholesterolemia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.